Janssens, Maaike (2022) The resensitization of cancer cells to CAR-T cell therapy after acquiring resistance by immune escape mechanisms. Master's Thesis / Essay, Biomolecular Sciences.
|
Text
mMBB_2022_JanssensMH.pdf Download (413kB) | Preview |
|
![[img]](https://fse.studenttheses.ub.rug.nl/style/images/fileicons/text.png) |
Text
toestemming.pdf Restricted to Registered users only Download (132kB) |
Abstract
Currently, a lot of research is being done on CAR-T cell therapy because of its very promising therapeutic benefits in the treatment of relapsed and refractory cancers, especially in hematological malignancies (Haslauer et al. 2021). These promising results have led to already several FDA-approved CAR-T cell therapies, with in particular anti-CD19-CAR-T cells (Sterner and Sterner 2021). Although hematological malignancies are easier to target with respect to more uniformly expressed targetable tumor antigens and easier contact of the CAR-T cells with hematologic cancer cells than solid tumors, major improvements are also made in CAR-T cell therapy against solid tumors (Marofi et al. 2021). However, cancer cells developed all kinds of mechanisms to escape antitumor responses from the immune system (Tang et al. 2020). Because CAR-T cells are part of the immune system, cancer cells can use similar mechanisms to evade the antitumor effects of CAR-T cell therapy and become resistant to it. Here, the TME with its immune checkpoints and antigen escape were discussed in detail.
| Item Type: | Thesis (Master's Thesis / Essay) |
|---|---|
| Supervisor name: | Linskens, M.H.K. |
| Degree programme: | Biomolecular Sciences |
| Thesis type: | Master's Thesis / Essay |
| Language: | English |
| Date Deposited: | 17 Mar 2022 09:28 |
| Last Modified: | 17 Mar 2022 09:28 |
| URI: | https://fse.studenttheses.ub.rug.nl/id/eprint/26711 |
Actions (login required)
 |
View Item |